Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant streptococcus pneumoniae carriage in young children 6 months after treatment

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1519-1526

  Coles, Christian L ^a   Mabula, Kasubi ^b   Seidman, Jessica C ^a   Levens, Joshua ^c   Mkocha, Harran ^d   Munoz, Beatriz ^c   Mfinanga, Sayoki G ^e   West, Sheila ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Kongwa Trachoma Project   (Tanzania)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

antimicrobial resistance; azithromycin; children; S. pneumoniae; trachoma

Indexed keywords

AZITHROMYCIN; COTRIMOXAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; DISEASE CARRIER; DISK DIFFUSION; EPSILOMETER TEST; FEMALE; HUMAN; INFANT; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; NASOPHARYNX; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; TRACHOMA; TREATMENT OUTCOME;

ANTIMICROBIAL RESISTANCE; AZITHROMYCIN; CHILDREN; S. PNEUMONIAE; TRACHOMA;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CARRIER STATE; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; PREVALENCE; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; TANZANIA; TRACHOMA;

EID: 84877286146     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit137     Document Type: Article

References (29)

1. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009; 93:563-8.
2. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351:1962-71.
3. West SK, Munoz B, Mkocha H, et al. Infection with Chlamydia tracho-matis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366:1296-300.
4. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromy-cin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tige-cycline). Med Clin North Am 2011; 95:761-91, viii.
5. Swainston HT, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007; 67:773-92.
6. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008; CD001954.
7. Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg 2011; 85:691-6.
8. Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 2012; 31:341-6.
9. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithro-mycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962-8.
10. Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011; 52:883-8.
11. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902.
12. Haug S, Lakew T, Habtemariam G, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 2010; 51:571-4.
13. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11:107-18.
14. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369: 482-90.
15. Malhotra-Kumar S, Coenen S, Klugman KP, Goossens H. 3-monthly azithromycin administration for trachoma. Lancet 2009; 374:449-50.
16. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneu-mococci. Emerg Infect Dis 2005; 11:802-7.
17. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87.
18. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-97.
19. World Health Organization. Integrated management of childhood illness. 2008. Geneva, Switzerland: WHO.
20. O'Brien KL, Bronsdon MA, Dagan R, et al. Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 2001; 39:1021-4.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard. 10th ed. M2-A210. 12-30-2008. Wayne, PA: CLSI.
22. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997; 24:356-62.
23. Batt SL, Charalambous BM, Solomon AW, et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2765-9.
24. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002; 35:395-402.
25. Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005; 5:481-93.
26. Laxminarayan R, Heymann DL. Challenges of drug resistance in the developing world. BMJ 2012; 344:e1567. doi:10.1136/bmj.e1567.:e1567.
27. Felmingham D, Canton R, Jenkins SG Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55:111-8.
28. Cars O, Hedin A, Heddini A. The global need for effective antibiotics-moving towards concerted action. Drug Resist Updat 2011; 14:68-9.
29. Nugent R, Okeke IN. When medicines fail: recommendations for curbing antibiotic resistance. J Infect Dev Ctries 2010; 4:355-6.